TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07712588: A Phase 2/3, Randomized, Double-Blind, Multi-center Study of Birelentinib Combined With R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma

Sponsor: Dizal Pharmaceuticals · Phase: PHASE2/PHASE3 · Area: ONCOLOGY · Target Enrollment: 880 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$18,036,480

Rescue Site Savings

+$11,892,804

Unlock Full NCT07712588 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07712588 Rescue Dossier →